Skip to main content
RaQualia Pharma Inc. logo

RaQualia Pharma Inc. — Investor Relations & Filings

Ticker · 4579 ISIN · JP3967150008 T Professional, scientific and technical activities
Open in API
Filings indexed 89 across all filing types
Latest filing 2021-05-14 Interim / Quarterly Rep…
Country JP Japan
Listing T 4579

About RaQualia Pharma Inc.

https://www.raqualia.com/en/index.html

RaQualia Pharma Inc. is a research and development-focused pharmaceutical company that specializes in the discovery and development of innovative small molecule compounds. The company's primary activities involve conducting exploratory research to identify novel drug candidates and advancing them through preclinical and clinical studies. Its business model centers on creating value by out-licensing the intellectual property of these compounds to other pharmaceutical companies for final development and commercialization. A key product originating from its research is tegoprazan (K-CAB®), a potassium-competitive acid blocker used for treating gastroesophageal reflux disease and other acid-related conditions.

Recent filings

Filing Released Lang Actions
四半期報告書－第14期第1四半期(令和3年1月1日－令和3年3月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for RaQualia Pharma Inc. for the first quarter of 2021 (period ending March 31, 2021). It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement, as well as management's analysis of financial results. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-14 Japanese
内部統制報告書－第13期(令和2年1月1日－令和2年12月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the company's framework, scope, and evaluation results regarding internal controls over financial reporting. This type of regulatory filing, which focuses on internal control compliance rather than general financial results or governance, is best categorized as a Regulatory Filing (RNS) as it does not fit into the specific categories of Annual Report (10-K) or Audit Report (AR) in the provided schema.
2021-03-30 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act. It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 2020
2021-03-30 Japanese
有価証券報告書－第13期(令和2年1月1日－令和2年12月31日)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of a 10-K annual report. It contains detailed financial statements, management information, and business indicators for the fiscal year ending December 31, 2020. It is a comprehensive annual filing, not an announcement or a summary. FY 2020
2021-03-30 Japanese
四半期報告書－第13期第3四半期(令和2年7月1日－令和2年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for RaQualia Pharma Inc., covering the third quarter of the fiscal year 2020 (ending September 30, 2020). It contains detailed financial statements, including the balance sheet, income statement, and cash flow statement, as well as management's analysis of financial conditions and results of operations. This fits the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-13 Japanese
四半期報告書－第13期第2四半期(令和2年4月1日－令和2年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for RaQualia Pharma Inc., covering the period from April 1, 2020, to June 30, 2020. It contains detailed financial statements, including the balance sheet, income statement, and cash flow analysis, as well as management's discussion and analysis. This fits the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-14 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.